{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:05:51Z","timestamp":1789239951427,"version":"build-2803163510"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients commonly experience chemotherapy-induced peripheral neuropathy (CIPN) as an adverse effect from chemotherapies, such as taxanes. In some patients, CIPN symptoms are severe and significantly impact their quality of life. Gaining a deeper understanding of how patient factors change over time, and identifying predisposing patient factors for CIPN susceptibility, could provide opportunities to mitigate the risk of CIPN and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 229 patients with breast cancer receiving taxane chemotherapy completed study visits over 12 months. Data from patient reported outcomes (PROs) were collected from validated questionnaires to assess CIPN, anxiety, depression, weight, physical function, and sleep disturbance. Wilcoxon signed-rank tests were conducted to evaluate changes in PROs between timepoints (pre-treatment, on-treatment, post-treatment). Logistic regression was used to compare PROs between CIPN and non-CIPN groups at each time point, after adjustment for age, race, and pre-treatment CIPN score. Results were adjusted for multiple comparisons using a false discovery rate (FDR) procedure (FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u2009.05). A random forest model using 19 patient features was employed to build a CIPN predictive model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 229 patients, 75% developed CIPN. Higher depression scores were associated with CIPN development across the three time periods: pre-treatment (OR\u2009=\u20091.20, FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20095.3\u2009\u00d7\u200910\n                      <jats:sup>\u2212<\/jats:sup>\n                      3), on-treatment (OR\u2009=\u20091.32, FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20094.4\u2009\u00d7\u200910\n                      <jats:sup>\u2212<\/jats:sup>\n                      4), and post-treatment (OR\u2009=\u20091.24, FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20094.3\u2009\u00d7\u200910\n                      <jats:sup>\u2212<\/jats:sup>\n                      3). Similarly, pre-treatment PROMIS physical function T scores were lower among patients who developed CIPN (FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20091.30\u2009\u00d7\u200910\n                      <jats:sup>\u22122<\/jats:sup>\n                      ), on-treatment (FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20095.78\u2009\u00d7\u200910\n                      <jats:sup>\u22126<\/jats:sup>\n                      ) and post-treatment (FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20098.7\u2009\u00d7\u200910\n                      <jats:sup>\u22125<\/jats:sup>\n                      ). On treatment anxiety scores were higher on-treatment in patients experiencing CIPN (OR\u2009=\u20091.30, FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20094.3\u2009\u00d7\u200910\n                      <jats:sup>\u22123<\/jats:sup>\n                      ). Patients with obesity were 3.78 times more likely to develop CIPN compared to those with normal weight (FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20093\u2009\u00d7\u200910\n                      <jats:sup>\u22123<\/jats:sup>\n                      ). Patients with CIPN did not report experiencing higher levels of sleep disturbance (FDR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u2009.05). The random forest predictive model reached an accuracy of 84% with body mass index (BMI), physical function score and general anxiety score as the most important predictors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate that those experiencing CIPN were more likely to report reduced physical functioning, increased anxiety and depression, and have higher BMIs. As new multi-modal approaches are developed for CIPN, pre-treatment physical functioning, BMI and other patient reported measures may provide predictive ability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpain.2026.1619858","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:42:57Z","timestamp":1769755377000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Time-course based assessment of patient factors and their relationship to chemotherapy induced peripheral neuropathy"],"prefix":"10.3389","volume":"7","author":[{"given":"Carla","family":"Bou Dargham","sequence":"first","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland Clinic","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Utah","place":["Salt Lake City, UT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Utah","place":["Salt Lake City, UT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihua","family":"Bie","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Cleveland Clinic","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Rhoades","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Steenblik","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Utah","place":["Salt Lake City, UT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Hershberger","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland Clinic","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wei","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah","place":["Salt Lake City, UT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School","place":["Ann Arbor, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anukriti","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland Clinic","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Thomas","family":"Budd","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Cleveland Clinic","place":["Cleveland, OH, United States"]},{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University","place":["Cleveland, OH, United States"]},{"name":"Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Foss","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Cleveland Clinic","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Rotroff","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland Clinic","place":["Cleveland, OH, United States"]},{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University","place":["Cleveland, OH, United States"]},{"name":"Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine","place":["Cleveland, OH, United States"]},{"name":"Center for Quantitative Metabolic Research, Cleveland Clinic","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00520-023-08209-0","article-title":"Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy","volume":"32","author":"Hertz","year":"2023","journal-title":"Support Care Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy: where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102241","DOI":"10.1016\/j.ctrv.2021.102241","article-title":"Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced peripheral neuropathy (CIPN)","volume":"99","author":"Hertz","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamaoncol.2019.4668","article-title":"Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer","volume":"6","author":"Feliciano","year":"2020","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2407-11-131","article-title":"Evaluating the impact of relative total dose intensity (RTDI) on patients\u2019 short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis","volume":"11","author":"Loibl","year":"2011","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1007\/s00520-019-04987-8","article-title":"Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview","volume":"27","author":"Chan","year":"2019","journal-title":"Support Care Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2070","DOI":"10.1002\/onco.13933","article-title":"Health-related quality of life in cancer survivors with chemotherapy-induced peripheral neuropathy: a randomized clinical trial","volume":"26","author":"Bao","year":"2021","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1007\/s00520-022-07093-4","article-title":"Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer","volume":"30","author":"Verhoeff-Jahja","year":"2022","journal-title":"Support Care Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/pon.5176","article-title":"Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: results from the population-based PROFILES registry","volume":"28","author":"Bonhof","year":"2019","journal-title":"Psychooncology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpainsymman.2019.04.029","article-title":"Deleterious effects of higher body mass index on subjective and objective measures of chemotherapy-induced peripheral neuropathy in cancer survivors","volume":"58","author":"Petrovchich","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2036695","DOI":"10.1001\/jamanetworkopen.2020.36695","article-title":"Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy","volume":"4","author":"Mizrahi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00520-017-4013-0","article-title":"Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial","volume":"26","author":"Kleckner","year":"2018","journal-title":"Support Care Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00520-023-08245-w","article-title":"Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes","volume":"32","author":"Mahfouz","year":"2023","journal-title":"Support Care Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2008.06.026","article-title":"The PHQ-8 as a measure of current depression in the general population","volume":"114","author":"Kroenke","year":"2009","journal-title":"J Affect Disord"},{"key":"B19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3928\/0048-5713-20020901-06","article-title":"The PHQ-9: a new depression diagnostic and severity measure","volume":"32","author":"Kroenke","year":"2002","journal-title":"Psychiatr Ann"},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jad.2012.11.052","article-title":"A comparison of the PRIME-MD PHQ-9 and PHQ-8 in a large military prospective study, the millennium cohort study","volume":"148","author":"Wells","year":"2013","journal-title":"J Affect Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/sleep\/33.6.781","article-title":"Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments","volume":"33","author":"Buysse","year":"2010","journal-title":"Sleep"},{"key":"B24","article-title":"PROMIS Physical Function User Manual and Scoring Instructions (2023)","year":""},{"key":"B25","article-title":"PROMIS Sleep Disturbance Scoring Manual (2021)","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/CORR.0000000000002046","article-title":"How do PROMIS scores correspond to common physical abilities?","volume":"480","author":"Brodke","year":"2022","journal-title":"Clin Orthop Relat Res"},{"key":"B27","article-title":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing","year":"2022"},{"key":"B28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"B29","author":"Wickham","year":""},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1201\/9781003089032","volume-title":"Tree-Based Methods for Statistical Learning in R","author":"Greenwell","year":"2022"},{"key":"B33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.32614\/RJ-2014-008","article-title":"ROSE: a package for binary imbalanced learning","volume":"6","author":"Lunardon","year":"2014","journal-title":"R J"},{"key":"B35","article-title":"Classification and Regression by Random Forest (2002)","author":"Liaw","year":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jclinepi.2009.11.009","article-title":"Use of brier score to assess binary predictions","volume":"63","author":"Rufibach","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"927.e1","DOI":"10.1016\/j.jhsa.2021.01.023","article-title":"Establishing the minimal clinically important difference for the PROMIS upper extremity computer adaptive test version 2.0 in a nonshoulder hand and upper extremity population","volume":"46","author":"Kazmers","year":"2021","journal-title":"J Hand Surg Am"},{"key":"B38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2217\/pmt-2018-0020","article-title":"An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy","volume":"8","author":"Boyette-Davis","year":"2018","journal-title":"Pain Manag"},{"key":"B39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychores.2018.02.012","article-title":"Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer","volume":"108","author":"Lee","year":"2018","journal-title":"J Psychosom Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/cam4.3129","article-title":"Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy","volume":"9","author":"Bennedsgaard","year":"2020","journal-title":"Cancer Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1327318","DOI":"10.3389\/fonc.2024.1327318","article-title":"Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study","volume":"14","author":"Lixian","year":"2024","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1523\/JNEUROSCI.1691-21.2021","article-title":"Neuroendocrine stress axis-dependence of duloxetine analgesia (anti-hyperalgesia) in chemotherapy-induced peripheral neuropathy","volume":"42","author":"Staurengo-Ferrari","year":"2022","journal-title":"J Neurosci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","article-title":"Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures","volume":"30","author":"Terwee","year":"2021","journal-title":"Qual Life Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12876-024-03227-6","article-title":"Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer","volume":"24","author":"Lin","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"djw206","DOI":"10.1093\/jnci\/djw206","article-title":"BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: the pathways study","volume":"109","author":"Greenlee","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B46","doi-asserted-by":"publisher","first-page":"112967","DOI":"10.1016\/j.expneurol.2019.112967","article-title":"Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease?","volume":"320","author":"Elzinga","year":"2019","journal-title":"Exp Neurol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/NCC.0000000000000693","article-title":"A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among cancer patients","volume":"43","author":"Dhawan","year":"2020","journal-title":"Cancer Nurs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/NCC.0000000000000682","article-title":"Effects of exercise interventions on breast cancer patients during adjuvant therapy: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Lee","year":"2020","journal-title":"Cancer Nurs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12885-019-5896-6","article-title":"Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the \u201cAPAD1\u201d randomized controlled trial","volume":"19","author":"Carayol","year":"2019","journal-title":"BMC Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1619858\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:27:32Z","timestamp":1771925252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1619858\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":50,"alternative-id":["10.3389\/fpain.2026.1619858"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2026.1619858","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1619858"}}